N
0.175
0.01 (6.06%)
| Previous Close | 0.165 |
| Open | 0.170 |
| Volume | 106,700 |
| Avg. Volume (3M) | 511,894 |
| Market Cap | 86,153,544 |
| Price / Sales | 7.36 |
| Price / Book | 7.61 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Operating Margin (TTM) | 26,926.24% |
| Diluted EPS (TTM) | -0.020 |
| Current Ratio (MRQ) | 12.42 |
| Operating Cash Flow (TTM) | -5.17 M |
| Levered Free Cash Flow (TTM) | -3.65 M |
| Return on Assets (TTM) | -42.14% |
| Return on Equity (TTM) | -126.08% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | NEURITHERA FPO [NUZ] | - | - |
AIStockmoo Score
-0.4
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | -0.38 |
|
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 27.86% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |